

## Studies support role of BioTheranostics' tests, 7/15

**July 2015—BioTheranostics announced that clinical study data disclosed at the** American Society of Clinical Oncology annual meeting in June demonstrate that its CancerType ID molecular cancer classifier and CancerTreatment NGS+ biomarker tests provide actionable genomic information to support an accurate diagnosis and treatment of metastatic cancers.

A prospective, multicenter study that included 444 patients assessed the utility and impact of CancerType ID in treatment decision-making in community clinical practice. The study demonstrated significant clinical utility of the test, changing treatment decisions in about half of patients. Clinical utility spanned a spectrum of diagnostic uncertainty for oncologists and pathologists and helped narrow the differential diagnosis. Diagnosis of lung or colorectal cancer by CancerType ID commonly informed the use of additional biomarker testing in the study.

A second retrospective study assessed the actionability of a combinatorial approach using the CancerType ID assay followed by multiplatform biomarker profiling with CancerTreatment NGS+ in a large series of cases with unknown or uncertain origin that were identified as non-small cell lung cancer by CancerType ID. Results demonstrate the clinical utility of a combinatorial approach using molecular diagnosis of tumor type and comprehensive multiplatform mutational profiling to enable precision medicine with tumor-specific and molecularly targeted treatment options.

**[BioTheranostics](#)**, 877-886-6739